CB: "We haven't given guidance, but there's no particular reason for our R&D expenditure to accelerate. So it's obviously always a little bit chunky because we've got clinical trials and manufacturing activity that's going to be there. There shouldn't be any sticker shock on R&D for '23 and it will be funded through earnings and will not be funded to a capital increase".
Confirmed
Ann: 2022 Full Year Results Presentation, page-44
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.48 |
Change
0.030(0.15%) |
Mkt cap ! $6.854B | |||
| Open | High | Low | Value | Volume |
| $20.35 | $20.83 | $20.30 | $10.68M | 520.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1586 | $20.48 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.58 | 898 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| TLX (ASX) Chart |